


About us Profile Management Scientific Advisory Board Strategic alliances Partners Top articles Publications Platform technologies Nested Chemical Library The concept of Nested Chemical Library Chemical Validation Library Master library Hit finding Allosteric library Allosteric library Developing novel allosteric inhibitors Masterkey The Masterkey concept Masterkeys from the Nested Chemical Library Pharmacophore modeling Scaffold hopping The concept of scaffold hopping Scaffold hopping based lead finding Lead optimization - ADMET Lead generation Lead optimization Experimental ADMET parameters KinaTor Services Hit and lead finding Kinase inhibitor library In vitro biology Lead and ADMET optimization Target fishing Predictive QSAR Custom synthesis Process development Drug discovery Drug discovery programs Epilepsy EGFR HIV Influenza Neurogenic inflammation Tuberculosis Tumor stem cells Contact us

Drugs against cancer stem cells CSC-Stemkill™

NIH-Stem Cell Information

We offer a cutting-edge drug development project which can result in some ultimate weapons in the war against cancer. The goal in cancer treatment would be to permanently eradicate all cancer cells from a particular patient. In many cases, however, a seemingly successful treatment ends in disease relapse owing to the survival of a small population of dormant cancer stem cells that are resistant to chemotherapy. According to the widely accepted cancer stem cell concept it is possible to vanish entirely the targeted tumour and to prevent metastasis and remission. Our goal is not smaller than to develop drugs that can eliminate certain types of cancer from a particular patient forever, via killing differentiated cancer cells and even cancer stem cells with the efficient inhibition of a certain set of survival factors, based on a proper and sophisticated molecular diagnostics.

This project is very challenging and risky, however its possible financial and social benefits are undoubtedly tremendous. Although it is a start-up project, we have already had encouraging results.

Our cancer stem cell killing program is accomplished with the following steps:

Using our NCL™ kinase inhibitor library we have developed and will further develop kinase inhibitors which kill more than 95% of certain cancer cells (including cancer stem cells).
Using our Oncompass™ diagnostics tool and target fishing technology we identify the molecular genetic, gene expression and proteomic profile of the cancer stem cells.
We provide a personalized therapy and molecular diagnostic protocol using tumour samples to select those patients who will respond to a particular cancer stem cell killing drug.

Results

Although this is a start-up project, we have already identified some very promising hit compounds. Six of them are patentable and according to in vitro toxicity assays they are not toxic. One of these compounds has been involved in preliminary in vivo assay with a quite promising result. All of these potential drug candidates are in the beginning of the hit-to-lead development process.